The boundaries between aesthetic medicine, preventative health and longevity are becoming increasingly blurred. Patients are no longer visiting aesthetic clinics simply to address visible signs of ageing, now they want to feel better and live longer and healthier too.
For some clinics, this is creating a natural evolution of their practice. Conversations about skin ageing may now sit alongside discussions about hormones, metabolic health, sleep and nutrition, while services can extend into diagnostic testing, intravenous (IV) nutrient therapy and more comprehensive healthspan programmes.
But moving from aesthetics into longevity or functional medicine is not simply a case of adding another treatment to the clinic menu. These services can introduce different clinical, regulatory and insurance considerations.
So, where does aesthetics meet longevity medicine, and what should practitioners consider before expanding into this developing area?
There is no single definition of ‘longevity medicine’. Broadly, the term describes an approach focused on extending healthspan – the number of years a person spends in good health – rather than simply lifespan.
In an aesthetic or integrated clinic, this might include:
Some clinics may build comprehensive longevity programmes around several of these services. Others may simply take a more integrated approach to consultation, recognising that skin, appearance and ageing do not exist in isolation from wider health.
In many ways, the crossover between aesthetics and longevity medicine makes sense. People who are already investing in their appearance may also be motivated to invest in their long-term health. An aesthetic consultation can open conversations about concerns such as fatigue, weight changes, poor sleep, hair loss or changes in skin quality, all of which may have a wider health context.
Longevity medicine also complements the growing interest in regenerative medicine. Both approaches reflect a shift away from simply treating the visible signs of ageing towards supporting the biological processes that influence how we age.
The growing focus on prevention is also changing expectations. Rather than waiting for visible ageing or disease to develop, some patients want to understand their personal risk factors and take action earlier.
For clinics, this can create opportunities to develop longer-term patient relationships and diversify beyond episodic aesthetic treatments. Of course, it also offers attractive additional revenue streams something we are seeing play out as, internationally, premium clinics are increasingly combining aesthetics with diagnostics, hormone health, metabolic medicine and other preventative services.
There is also genuine clinical logic behind taking a wider view of the patient. Hormonal changes, metabolic health, nutrition, sleep, stress and underlying disease can all influence skin health, healing and ageing.
However, recognising those connections is different from being qualified to diagnose or treat them.
An aesthetic practitioner can take a whole-person view without automatically becoming a functional medicine practitioner, hormone specialist or longevity clinician. As services become more medical, practitioners need to be particularly clear about their competence, scope of practice and referral pathways.
One of the biggest challenges within longevity medicine is that the term encompasses interventions with very different levels of evidence behind them.
Lifestyle interventions such as physical activity, smoking cessation, adequate sleep and appropriate nutrition have substantial evidence supporting their role in long-term health. Established hormone therapies may also have recognised clinical indications and evidence-based prescribing frameworks.
Other interventions marketed under the longevity umbrella are much newer, supported by emerging or limited evidence, or remain the subject of scientific debate.
A plausible biological mechanism does not necessarily translate into proven clinical benefit. A biomarker changing after an intervention does not automatically mean that someone will live longer or remain healthier for longer.
Practitioners should be able to explain what is established, what is emerging and what remains uncertain. Claims made through consultations, websites and social media should reflect the available evidence, and consent should include realistic discussion of potential benefits, limitations and risks.
Managing expectations is not only part of good clinical practice. It can also help reduce the risk of dissatisfaction and complaints.
There is another consideration too: more testing does not always mean better medicine.
Broad diagnostic panels, genetic information and biological age testing can generate findings that require careful interpretation. Incidental or borderline results may cause anxiety, lead to further investigations or create a risk of overdiagnosis.
If you offer testing, you need a clear plan for what happens after the result arrives.
As clinics expand, insurance needs to evolve with them. One of the biggest mistakes a practitioner can make is assuming that because they already hold medical malpractice insurance for aesthetic treatments, every new health or wellness service they introduce is automatically covered.
Your policy schedule sets out the treatments and procedures your policy covers. Adding IV therapy, diagnostic services, hormone-related treatment or other longevity interventions may introduce activities that sit outside your existing cover.
Before introducing any new service, speak to your insurer and explain exactly what you plan to offer.
Do this before you invest in training, equipment or marketing. Your insurer may have specific requirements around qualifications, training providers, protocols, premises or professional registration.
Hormone optimisation can move a clinic into a very different area of clinical responsibility.
Prescription-only medicines must be prescribed by an appropriately qualified prescriber acting within their competence and professional standards. Prescribers are responsible for clinical assessment, whether a medicine is appropriate, ongoing monitoring and follow-up.
The position can become more complex when medicines are prescribed off-label or are unlicensed.
An unlicensed medicine may sometimes be prescribed to meet a patient’s specific clinical needs, but this carries additional professional responsibilities. Practitioners need to understand the regulatory status of anything they prescribe or administer and the standards set by their professional regulator.
The same caution applies to the growing interest in peptide therapies. ‘Peptide’ describes a broad category rather than a single type of treatment, and it is important not to conflate established peptide-based medicines with the newer compounds gaining attention in longevity and biohacking circles. Peptides have a long history in medicine: insulin is a peptide hormone, while glucagon-like peptide-1 (GLP-1) receptor agonists are now widely used in the management of type 2 diabetes and obesity. These sit within established regulatory and prescribing frameworks.
However, growing interest in longevity has brought a very different group of peptides into the spotlight, with compounds promoted for purposes ranging from tissue repair and recovery to metabolic health, body composition and healthy ageing. In many cases, the scientific mechanisms may be of genuine research interest, but robust human clinical evidence remains limited, and products promoted online may not be licensed or authorised for human use in the UK.
This creates particular risks around sourcing and supply. Products sold as ‘research use only’ are not automatically suitable or lawful for administration to patients, and products obtained outside legitimate pharmaceutical supply chains may raise concerns around purity, dosage accuracy, sterility, storage and traceability.
Practitioners should therefore assess each peptide individually rather than viewing ‘peptide therapy’ as a single treatment category. Before prescribing, supplying or administering any peptide-based intervention, check its regulatory status, the evidence supporting the proposed use, whether there is a legitimate route of supply and whether the activity falls within your professional scope and insurance cover. Patient demand or growing popularity within longevity medicine does not, on its own, establish that a treatment is safe, evidence-based or appropriate to offer.
Your insurer should also know about the prescribing activities you carry out so that you can check whether these fall within the scope of your cover.
IV nutrient therapy may sit comfortably alongside the wellness positioning of a longevity clinic, but clinically it is an invasive procedure.
Potential complications can include infection, allergic or anaphylactic reactions, extravasation, fluid or electrolyte problems and other adverse reactions depending on what is administered and the patient’s underlying health.
Insurers may therefore want to know about your qualifications and training, what substances you plan to administer, your patient selection and screening processes, and how you manage emergencies and complications.
Completing a training course does not automatically mean an insurer will cover you to carry out the treatment. Check the insurer’s requirements before enrolling.
Diagnostic testing can sometimes appear lower risk because there is no injectable treatment or physical procedure involved. But liability does not end with taking a blood sample or sending a test to a laboratory.
If you order a test, interpret the result and make a clinical recommendation based on it, you are making clinical decisions.
Questions to consider include: Are you appropriately qualified to order and interpret that test? What happens if you miss an abnormal result? What is your process for communicating clinically significant findings? When do you refer to a GP or specialist? And who is responsible for follow-up?
The more complex the diagnostic offering becomes, the more important clear clinical governance, record keeping, referral pathways and appropriate insurance become.
Moving into longevity medicine may also change your regulatory responsibilities.
Depending on the services provided, the professionals delivering them and how care is structured, activities such as diagnosis, treatment of disease or disorder, and certain diagnostic and screening procedures may fall within the scope of CQC regulation in England. In Northern Ireland, independent healthcare services are regulated by the Regulation and Quality Improvement Authority (RQIA), in Wales by Health Inspectorate Wales (HIW) and in Scotland by Health Improvement Scotland (HIS).
Do not assume that because your existing aesthetic treatments do not require registration, a new medical or diagnostic service will be treated in the same way.
Take appropriate advice before launching the service and check the requirements of your professional regulator, the relevant healthcare regulator and your insurer.
If you are considering expanding into longevity or functional medicine, start with the foundations:
Longevity medicine reflects a wider change in how patients think about ageing. For many, looking well is increasingly connected with feeling well, functioning well and remaining healthy for longer.
Aesthetic clinics are well placed to be part of that conversation. But there is a significant difference between broadening the lens through which you view a patient and broadening your clinical scope.
For practitioners with appropriate qualifications, governance and insurance, longevity and functional medicine may offer opportunities to develop more integrated models of care and longer-term patient relationships. The key is to build from strong foundations.
Before adding hormone services, IV therapy, diagnostic testing, peptide therapies or any other longevity-focused treatment, speak to Hamilton Fraser about your plans and check what your medical malpractice insurance covers.
You can get an online quote or call us on 0800 63 43 881.
